Feasibility of Semaglutide in Advanced Lung Disease
Status:
Not yet recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment
for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.
The main question[s] it aims to answer are:
1. Are patients with advanced lung disease able to tolerate semaglutide therapy?
2. Are we able to titrate semaglutide therapy to a target weight?
Participants will be asked to perform pulmonary function, physical function and body
composition testing, as well as a blood draw before and after 12-weeks of semaglutide
therapy. While on therapy, subjects will be surveyed regarding any adverse events or side
effects.